Design of nanomaterial based systems for novel vaccine development

Biomaterials Science

Volumn 4, Issue 5, 2016, Pages 785-802

  Yang, Liu ^a   Li, Wen ^b   Kirberger, Michael ^c   Liao, Wenzhen ^a   Ren, Jiaoyan ^a  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b Ihrc Inc   (United States)

^c CLAYTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; DESIGN; LIPOSOMES; NANOSTRUCTURED MATERIALS; PEPTIDES; VACCINES; VIRUSES;

IMMUNE RESPONSE; MATERIAL SCIENCE; MICRONEEDLE ARRAYS; PEPTIDE AMPHIPHILES; POLYMERIC NANOPARTICLES; PROCESSING STEPS; VACCINE DEVELOPMENT; VIRUS-LIKE PARTICLES;

DISEASES;

AMPHOPHILE; LIPOSOME; NANOFIBER; NANOMATERIAL; POLYGLACTIN; POLYPEPTIDE; POLYPROPYLENE; VACCINE; MICELLE; NANOPARTICLE; VIRUS LIKE PARTICLE VACCINE;

DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; IMMUNOSTIMULATION; MICELLIZATION; MICRONEEDLE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS LIKE AGENT; CHEMISTRY; MICELLE; PROCEDURES; VACCINE IMMUNOGENICITY;

DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGENICITY, VACCINE; LIPOSOMES; MICELLES; NANOFIBERS; NANOPARTICLES; VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84966671726     PISSN: 20474830     EISSN: 20474849     Source Type: Journal    
DOI: 10.1039/c5bm00507h     Document Type: Review

References (140)

1. F. Sallusto A. Lanzavecchia K. Araki R. Ahmed From vaccines to memory and back Immunity 2010 33 451 463
2. R. Rappuoli C. W. Mandl S. Black E. DeGregorio Vaccines for the twenty-first century society Nat. Rev. Immunol. 2011 11 865 872
3. J. J. Moon B. Huang D. J. Irvine Engineering Nano- and Microparticles to Tune immunity Adv. Mater. 2012 24 3724 3746
4. D. J. Irvine M. A. Swartz G. L. Szeto Engineering synthetic vaccines using cues from natural immunity Nat. Mater. 2013 12 978 990
5. I. Melero G. Gaudernack W. Gerritsen et al., Therapeutic vaccines for cancer: an overview of clinical trials Nat. Rev. Clin. Oncol. 2014 11 509 524
6. O. Finco R. Rappuoli Designing vaccines for the twenty-first century society Front. Immunol. 2014 5 12
7. T. W. LeBien T. F. Tedder B lymphocytes: how they develop and function Blood 2008 112 1570 1580
8. A. Iwasaki R. Medzhitov Regulation of adaptive immunity by the innate immune system Science 2010 327 291 295
9. T. W. Mak and M. E. Saunders, Primer to the Immunity Response, Science Press, Beijing, 2012, pp. 117-118 (in Chinese)
10. B. Pulendran R. Ahmed Immunological mechanisms of vaccination Nat. Immunol. 2011 12 509 517
11. J. Zhu H. Yamane W. E. Paul Differentiation of effector CD4 T cell populations (∗). Annu. Rev. Immunol. 2010 28 445 489
12. J. Zhu W. E. Paul CD4 T cells: fates, functions, and faults Blood 2008 112 1557 1569
13. Y. Belkaid K. Tarbell Regulatory T cells in the control of host-microorganism interactions (∗) Annu. Rev. Immunol. 2009 27 551 589
14. S. E. Macatonia N. A. Hosken M. Litton et al., Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells J. Immunol. 1995 154 5071 5079
15. K. M. Murphy S. L. Reiner The lineage decisions of helper T cells Nat. Rev. Immunol. 2002 2 933 944
16. S. Crotty R. J. Johnston S. P. Schoenberger Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation Nat. Immunol. 2010 11 114 120
17. T. G. Phan E. E. Gray J. G. Cyster The microanatomy of B cell activation Curr. Opin. Immunol. 2009 21 258 265
18. D. P. Harris L. Haynes P. C. Sayles et al., Reciprocalregulation of polarized cytokine production by effector B and T cells Nat. Immunol. 2000 1 475 482
19. S. L. Swain K. Kai McKinstry T. M. Strutt Expanding roles for CD4+ T cells in immunity to viruses Nat. Rev. Immunol. 2012 12 136 148
20. J. C. Adkins A. J. Wagstaff a review of its immunogenicity and protective efficacy against hepatiti B BioDrugs 1998 10 2 137 158
21. M. Black A. Trent M. Tirrell C. Olive Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists Expert Rev. Vaccines 2010 9 157 173
22. A. W. Purcell J. McCluskey J. Rossjohn More than one reason to rethink the use of peptides in vaccine design Nat. Rev. Drug Discovery 2007 6 404 414
23. G. Galli K. Hancock K. Hoschler et al., Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine Proc. Natl. Acad. Sci. U. S. A. 2009 106 7962 7967
24. P. Vandepapeliere Y. Horsmans P. Moris et al., Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers Vaccine 2008 26 1375 1386
25. G. Galli D. Medini E. Borgogni et al., Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U. S. A. 2009 106 3877 3882
26. J. W. Huleatt A. R. Jacobs J. Tang et al., Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity Vaccine 2007 25 763 775
27. L. Malherbe L. Mark N. Fazilleau L. J. McHeyzer-Williams M. G. McHeyzer-Williams Vaccine adjuvants alter TCR-based selection thresholds Immunity 2008 28 698 709
28. R. L. Coffman A. Sher R. A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 2010 33 492 503
29. Modulation of the Immune Response to Vaccine Antigens Proceedings of a conference. Bergen, Norway, June 18-21, 1996 Dev. Biol. Stand. 1998 92 1 372
30. S. G. Reed M. T. Orr C. B. Fox Key roles of adjuvants in modern vaccines Nat. Med. 2013 19 1597 1608
31. N. Petrovsky J. C. Aguilar Vaccine adjuvants: current state and future trends Immunol. Cell Biol. 2004 82 488 496
32. M. Skocaj M. Filipic J. Petkovic S. Novak Titanium dioxide in our everyday life; is it safe? Radiol. Oncol. 2011 45 227 247
33. G. Oberdörster J. Ferin B. E. Lehnert Correlation between particle size, in vivo particle persistence, and lung injury Environ. Health Perspect. 1994 102 173 179
34. E. M. Ophus L. Rode B. Gylseth D. G. Nicholson K. Saeed Analysis of titanium pigments in human lung tissue Scand. J. Work, Environ. Health 1979 5 290 296
35. U. Taylor A. Barchanski W. Garrels S. Klein W. Kues S. Barcikowski D. Rath Toxicity of Gold Nanoparticles on Somatic and Reproductive Cells Adv. Exp. Med. Biol. 2012 733 125 133
36. G. Sonavane K. Tomoda K. Makino Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size Colloids Surf., B 2008 66 274 280
37. E. E. Connor J. Mwamuka A. Gole C. J. Murphy M. D. Wyatt Gold Nanoparticles Are Taken Up by Human Cells but Do Not Cause Acute Cytotoxicity Small 2005 1 325 327
38. Y. Pan A. Leifert D. Ruau S. Neuss J. Bornemann G. Schmid W. Brandau U. Simon W. Jahnen-Dechent Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage Small 2009 5 2067 2076
39. L. Mohr S. K. Yoon S. J. Eastman Q. Chu R. K. Scheule P. P. Scaglioni M. Geissler T. Heintges H. E. Blum J. R. Wands Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice Hum. Gene Ther. 2001 12 799 809
40. H. E. Hofland D. Nagy J. J. Liu K. Spratt Y. L. Lee O. Danos S. M. Sullivan In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex Pharm. Res. 1997 14 742 749
41. J. D. Tousignant A. L. Gates L. A. Ingram C. L. Johnson J. B. Nietupski S. H. Cheng S. J. Eastman R. K. Scheule Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice Hum. Gene Ther. 2000 11 2493 2513
42. J. R. Fitzpatrick J. R. Frederick3rd R. C. McCormick D. A. Harris A. Y. Kim J. R. Muenzer A. J. Gambogi J. P. Liu E. C. Paulson Y. J. Woo Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction J. Thorac. Cardiovasc. Surg. 2010 140 667 676
43. L. Yildirimer N. T. K. Thanh M. Loizidou A. M. Seifalian Toxicology and clinical potential of nanoparticles Nano Today 2011 6 585 607
44. H. Dollefeld K. Hoppe J. Kolny K. Schilling H. Weller A. Eychmuller Investigations on the stability of thiol stabilized semiconductor nanoparticles Phys. Chem. Chem. Phys. 2002 4 4747 4753
45. K. S. Soppimath T. M. Aminabhavi A. R. Kulkarni W. E. Rudzinski Biodegradable polymeric nanoparticles as drug delivery devices J. Controlled Release 2001 70 1 20
46. D. Goren A. T. Horowitz D. Tzemach M. Tarshish S. Zalipsky A. Gabizon Nuclear Delivery of Doxorubicin via Folate-targeted Liposomes with Bypass of Multidrug-resistance Efflux Pump Clin. Cancer Res. 2000 6 1949 1957
47. O. Nag V. Awasthi Surface Engineering of Liposomes for Stealth Behavior Pharmaceutics 2013 5 542 569
48. W. W. Unger A. J. van Beelen S. C. Bruijns M. Joshi C. M. Fehres L. van Bloois M. I. Verstege M. Ambrosini H. Kalay K. Nazmi J. G. Bolscher E. Hooijberg T. D. de Gruijl G. Storm Y. van Kooyk Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells J. Controlled Release 2012 160 88 95
49. G. Schreibelt L. J. Klinkenberg L. J. Cruz P. J. Tacken J. Tel M. Kreutz G. J. Adema G. D. Brown C. G. Figdor I. J. de Vries The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells Blood 2012 119 2284 2292
50. L. F. Poulin Y. Reyal H. Uronen-Hansson B. U. Schraml D. Sancho K. M. Murphy U. K. Hakansson L. Ferreira Moita W. W. Agace D. Bonnet C. Reis e Sousa DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues Blood 2012 119 6052 6062
51. C. M. Fehres W. W. J. Unger J. J. Garcia-Vallejo Y. van Kooyk Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer Front. Immunol. 2014 5 1 10
52. L. J. Brady Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against Microbial Antigens Infect. Immun. 2005 73 671 678
53. A. Kunkl G. G. Klaus The generation of memory cells. IV. Immunization with antigen-antibody complexes accelerates the development of B-memory cells, the formation of germinal centres and the maturation of antibody affinity in the secondary response Immunology 1981 43 371 378
54. Y. Phanse B. R. Carrillo-Conde A. E. Ramer-Tait S. Broderick C. S. Kong K. Rajan R. Flick R. B. Mandell B. Narasimhan M. J. Wannemuehler A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms Sci. Rep. 2014 4 3775 1 10
55. T. Nakamura K. Ono Y. Suzuki R. Moriguchi K. Kogure H. Harashima Octaarginine-Modified Liposomes Enhance Cross-Presentation by Promoting the C-Terminal Trimming of Antigen Peptide Mol. Pharmaceutics 2014 11 2787 2795
56. L. Zhao A. Seth N. Wibowo et al., Nanoparticle vaccines Vaccine 2014 32 327 337
57. G. T. Jennings M. F. Bachmann Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines Curr. Mol. Med. 2007 7 143 155
58. L. Treuel X. Jiang G. U. Nienhaus New views on cellular uptake and trafficking of manufactured nanoparticles J. R. Soc., Interface 2013 10 20120939
59. Y. Wen W. S. Meng Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors J. Pharm. Innov. 2014 9 158 173
60. Ye Liu Y. Xu Y. Tian C. Chen C. Wang X. Jiang Functional Nanomaterials Can Optimize the Efficacy of Vaccines Small 2014 22 4505 4520
61. P. Couvreur C. Vauthier Nanotechnology: intelligent design to treat complex disease Pharm. Res. 2006 23 1417 1450
62. S. M. Moghimi A. C. Hunter J. C. Murray Nanomedicine: current status and future prospects FASEB J. 2005 19 311 330
63. Y. Wen J. H. Collier Supramolecular peptide vaccines: tuning adaptive immunity Curr. Opin. Immunol. 2015 35 73 79
64. E. A. Scott A. Stano M. Gillard A. C. Maio-Liu M. A. Swartz J. A. Hubbell Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes Biomaterials 2012 33 6211 6219
65. J. J. Moon H. Suh M. E. Polhemus C. F. Ockenhouse A. Yadava D. J. Ivine Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine PLoS One 2012 7 e31472
66. G. Senti T. M. Kundig Intralymphatic immunotherapy World Allergy Organ. J. 2015 8 9
67. C. M. Jewlll C. Sandra B. Lopez D. J. Irvine in situ engineering of lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles Proc. Natl. Acad. Sci. U. S. A. 2011 108 38 15745 15750
68. C. Engman Y. Wen W. S. Meng R. Bottino M. Trucco N. Giannoukakis Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation Clin. Immunol. 2015 160 1 103 123
69. S. N. Thomas E. Vokali A. W. Lund J. A. Hubbell M. A. Swartz Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response Biomaterials 2014 35 814 824
70. A. de Titta M. Ballester Z. Julier et al., Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose Proc. Natl. Acad. Sci. U. S. A. 2013 110 19902 19907
71. M. Ballester C. Nembrini N. Dhar et al., Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis Vaccine 2011 29 6959 6966
72. S. Hirosue I. C. Kourtis A. J. van der Vlies J. A. Hubbell M. A. Swartz Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation Vaccine 2010 28 7897 7906
73. A. Stano C. Nembrini M. A. Swartz J. A. Hubbell E. Simeoni Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization Vaccine 2012 30 7541 7546
74. A. Stano A. J. van der Vlies M. M. Martino M. A. Swartz J. A. Hubbell E. Simeoni PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration Vaccine 2011 29 804 812
75. V. P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discovery 2005 4 145 160
76. C. Popescu S. Durbaca D. Ivanov Liposomes as immunological adjuvants for tetanus vaccine Rom. Arch. Microbiol. Immunol. 1998 57 263 269
77. S. D. Xiang A. Scholzen G. Minigo C. David V. Apostolopoulos P. L. Mottram M. Plebanski Pathogen recognition and development of particulate vaccines: does size matter Methods 2006 40 1 9
78. R. A. Schwendener Liposomes as vaccine delivery systems: a review of the recent advances Ther. Adv. Vaccines. 2014 2 159 182
79. J. J. Moon H. Suh A. Bershteyn et al., Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses Nat Mater. 2011 10 243 251
80. J. M. Jeong Y. C. Chung J. H. Hwang Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome J. Biotechnol. 2002 94 255 263
81. M. C. Hanson W. Abraham M. P. Crespo et al., Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides Vaccine 2015 33 861 868
82. J. J. Moon H. Suh A. V. Li C. F. Ockenhouse A. Yadava D. J. Irvine Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction Proc. Natl. Acad. Sci. U. S. A. 2012 109 1080 1085
83. S. Mahadevan A. L. Tappel Lysosomal lipases of rat liver and kidney J. Biol. Chem. 1968 243 2849 2854
84. J. J. Moon H. Suh M. E. Polhemus C. F. Ockenhouse A. Yadava D. J. Irvine Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine PLoS One 2012 7 2 e31472
85. A. V. Li J. J. Moon W. Abraham H. Suh J. Elkhader M. A. Seidman Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination Sci. Transl. Med. 2013 5 204 3006516
86. A. Hjalmsdottir C. Bühler V. Vonwil M. Roveri M. Håkerud Y. Wäckerle-Men B. Gander P. Johansen Cytosolic delivery of liposomal vaccines by means of concomitant photosensitisation of phagosomes Mol. Pharm. 2015 5b00394
87. C. Butts N. Murray A. Maksymiuk et al., Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J. Clin. Oncol. 2005 23 6674 6681
88. R. Noad P. Roy Virus-like particles as immunogens Trends Microbiol. 2003 11 438 444
89. E. V. Grgacic D. A. Anderson Virus-like particles: passport to immune recognition Methods 2006 40 60 65
90. F. Boato R. M. Thomas A. Ghasparian A. Freund-Renard K. Moehle J. A. Robinson Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system Angew. Chem., Int. Ed. 2007 46 9015 9018
91. L. F. Zhang J. Zhou S. Chen et al., HPV6b virus like particles are potent immunogens without adjuvant in man Vaccine 2000 18 1051 1058
92. M. F. Bachmann G. T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecularpatterns Immunology 2010 10 787 796
93. S. A. Kaba C. Brando Q. Guo et al., A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria J. Immunol. 2009 183 7268 7277
94. S. Babapoor T. Neef C. Mittelholzer et al., A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection Influenza Res. Treat. 2011 2011 126794
95. M. E. McCoy H. E. Golden T. A. Doll et al., Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine Malar. J. 2013 12 136
96. S. A. Kaba M. E. McCoy T. A. Doll et al., Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine PLoS One 2012 7 e48304
97. K. El Bissati Y. Zhou D. Dasgupta et al., Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice Vaccine 2014 32 3243 3248
98. F. Boato R. M. Thomas A. Ghasparian A. Freund-Renard K. Moehle J. A. Robinson Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system Angew. Chem., Int. Ed. 2007 46 9015 9018
99. A. Ghasparian T. Riedel J. Koomullil et al., Engineered synthetic virus-like particles and their use in vaccine delivery ChemBioChem 2011 12 100 109
100. R. Sharma A. Ghasparian J. A. Robinson K. C. McCullough Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis PLoS One 2012 7 e43248
101. S. Thrane C. M. Janitzek M. Agerbæk S. B. Ditlev M. Resende M. A. Nielsen T. G. Theander A. Salanti A. F. Sander A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA PLoS One 2015 10 11 e0143071
102. A. Banerjee H. Onyuksel Peptide delivery using phospholipid micelles Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2012 4 562 574
103. P. Simerska T. Suksamran Z. M. Ziora F. L. Rivera C. Engwerda I. Toth Ovalbumin lipid core peptide vaccines and their CD4(+) and CD8(+) T cell responses Vaccine 2014 32 4743 4750
104. M. Zaman S. Chandrudu A. K. Giddam et al., Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity Nanomedicine 2014 9 2613 2624
105. F. Azmi F. A. A. Ahmad A. K. Giddam et al., Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant Bioorg. Med. Chem. 2014 22 6401 6408
106. T. Y. Liu A. K. Giddam W. M. Hussein et al., Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model Curr. Drug Delivery 2015 12 3 8
107. K. White P. Kearns I. Toth S. Hook Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides Immunol. Cell Biol. 2004 82 517 522
108. P. M. Moyle J. Hartas A. Henningham M. R. Batzloff M. F. Good I. Toth An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system Nanomedicine 2013 9 935 944
109. M. Zaman A. B. Abdel-Aal Y. Fujita et al., Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship PLoS One 2012 7 e30146
110. A. Trent B. D. Ulery M. J. Black et al., Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination AAPS J. 2015 17 380 388
111. M. Vincenzi A. Accardo S. Costantini S. Scala L. Portella A. Trotta L. Ronga J. Guillon M. Leone G. Colonna F. Rossi D. Tesauro Intrinsically disordered amphiphilic peptides as potential targets in drug delivery vehicles Mol. BioSyst. 2015 11 2925 2932
112. M. Black A. Trent Y. Kostenko J. S. Lee C. Olive M. Tirrell Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo Adv. Mater. 2012 24 3845 3849
113. Y. Chen C. Tang J. Zhang M. Gong B. Su F. Qiu Self-assembling surfactant-like peptide A6 K as potential delivery system for hydrophobic drugs Int. J. Nanomed. 2015 10 847 858
114. J. S. Rudra T. Sun K. C. Bird et al., Modulating adaptive immune responses to peptide self-assemblies ACS Nano 2012 6 1557 1564
115. Y. Wen H. R. Kolonich K. M. Kruszewski N. Giannoukakis E. S. Gawalt W. S. Meng Retaining antibodies in tumors with a self-assembling injectable system Mol. Pharm. 2013 10 1035 1044
116. Y. Wen W. Liu C. Bagia et al., Antibody-functionalized peptidic membranes for neutralization of allogeneic skin antigen-presenting cells Acta Biomater. 2014 10 4759 4767
117. Y. Zheng Y. Wen A. M. George et al., A peptide-based material platform for displaying antibodies to engage T cells Biomaterials 2011 32 249 257
118. M. J. Saunders W. Liu C. Szent-Gyorgyi et al., Engineering fluorogen activating proteins into self-assembling materials Bioconjugate Chem. 2013 24 803 810
119. G. A. Hudalla T. Sun J. Z. Gasiorowski et al., Gradated assembly of multiple proteins into supramolecular nanomaterials Nat. Mater. 2014 13 829 836
120. R. R. Pompano J. Chen E. A. Verbus et al., Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs Adv. Healthcare Mater. 2014 3 1898 1908
121. J. Chen R. R. Pompano F. W. Santiago et al., The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation Biomaterials 2013 34 8776 8785
122. G. A. Hudalla J. A. Modica Y. F. Tian et al., A self-adjuvanting supramolecular vaccine carrying a folded protein antigen Adv. Healthcare Mater. 2013 2 1114 1119
123. T. S. Kupper R. C. Fuhlbrigge Immune surveillance in the skin: mechanisms and clinical consequences Nat. Rev. Immunol. 2004 4 211 222
124. M. Merad F. Ginhoux M. Collin Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells Nat. Rev. Immunol. 2008 8 935 947
125. F. O. Nestle M. P. Di J. Z. Qin B. J. Nickoloff Skin immune sentinels in health and disease Nat. Rev. Immunol. 2009 9 679 691
126. P. C. Demuth W. F. Garcia-Beltran M. L. Ai-Ling P. T. Hammond D. J. Irvine Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination Adv. Funct. Mater. 2013 23 161 172
127. E. L. Giudice J. D. Campbell Needle-free vaccine delivery Adv. Drug Delivery Rev. 2006 58 68 89
128. E. M. Saurer R. M. Flessner S. P. Sullivan M. R. Prausnitz D. M. Lynn Layer-by-layer assembly of DNA- and protein-containing films on microneedles for drug delivery to the skin Biomacromolecules 2010 11 3136 3143
129. P. C. DeMuth J. J. Moon H. Suh P. T. Hammond D. J. Irvine Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery ACS Nano 2012 6 8041 8051
130. P. C. DeMuth Y. Min D. J. Irvine P. T. Hammond Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization Adv. Healthcare Mater. 2014 3 47 58
131. K. van der Maaden E. Sekerdag P. Schipper G. Kersten W. Jiskoot J. Bouwstra Layer-by-Layer Assembly of Inactivated Poliovirus and N-Trimethyl Chitosan on pH-Sensitive Microneedles for Dermal Vaccination Langmuir 2015 31 8654 8660
132. T. Sun H. Han G. A. Hudalla Yi Wen R. R. Pompano J. H. Collier Thermal stability of self-assembled peptide vaccine materials Acta Biomater. 2016 30 62 71
133. V. Saini V. Jain M. S. Sudheesh S. Dixit R. L. Gaur M. K. Sahoo S. K. Joseph S. K. Verma K. S. Jaganathan P. K. Murthy D. Kohli Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres J. Drug Targeting 2010 18 212 222
134. C. Thomas A. Rawat L. Hope-Weeks F. Ahsan Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine Mol. Pharmaceutics 2011 8 405 415
135. M. Tyler E. Tumban D. S. Peabody B. Chackerian The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine Biotechnol. Bioeng. 2014 111 2398 2406
136. K. Pusic Z. Aguilar J. McLoughlin S. Kobuch H. Xu M. Tsang A. Wang G. Hui Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine FASEB J. 2012 27 1153 1166
137. D. Safari M. Marradi F. Chiodo H. A. ThDekker Y. Shan R. Adamo S. Oscarson G. T. Rijkers M. Lahmann J. P. Kamerling S. Penadés H. Snippe Gold nanoparticles as carriers for a syntheticStreptococcus pneumoniaetype 14 conjugate vaccine Nanomedicine 2012 7 651 662
138. X. Wang T. Uto T. Akagi M. Akashi M. Baba Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120 J. Virol. 2007 81 10009 10016
139. R. Sangha C. Butts L-BLP25: A Peptide Vaccine Strategy in Non-Small Cell Lung Cancer Clin. Cancer Res. 2006 13 4652s
140. J. H. Shannahan J. M. Brown Engineered nanomaterial exposure and the risk of allergic disease Curr. Opin. Allergy Clin. Immunol. 2014 14 2 95 99